These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12594105)

  • 21. ASAS/EULAR recommendations for the management of ankylosing spondylitis.
    Zochling J; van der Heijde D; Burgos-Vargas R; Collantes E; Davis JC; Dijkmans B; Dougados M; Géher P; Inman RD; Khan MA; Kvien TK; Leirisalo-Repo M; Olivieri I; Pavelka K; Sieper J; Stucki G; Sturrock RD; van der Linden S; Wendling D; Böhm H; van Royen BJ; Braun J; ;
    Ann Rheum Dis; 2006 Apr; 65(4):442-52. PubMed ID: 16126791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion.
    Dernis E; Lavie F; Pavy S; Wendling D; Flipo RM; Saraux A; Cantagrel A; Claudepierrre P; Goupille P; Le Loët X; Maillefert JF; Mariette X; Schaeverbeke T; Tebib J; Combe B
    Joint Bone Spine; 2007 Jul; 74(4):330-7. PubMed ID: 17590366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
    Dougados M; Wood E; Combe B; Schaeverbeke T; Miceli-Richard C; Berenbaum F; Koppiker N; Dubanchet A; Logeart I
    Arthritis Res Ther; 2014 Nov; 16(6):481. PubMed ID: 25428762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study.
    Haroon M; Ahmad M; Baig MN; Mason O; Rice J; FitzGerald O
    Arthritis Res Ther; 2018 Apr; 20(1):73. PubMed ID: 29665824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
    Calin A; Dijkmans BA; Emery P; Hakala M; Kalden J; Leirisalo-Repo M; Mola EM; Salvarani C; Sanmartí R; Sany J; Sibilia J; Sieper J; van der Linden S; Veys E; Appel AM; Fatenejad S
    Ann Rheum Dis; 2004 Dec; 63(12):1594-600. PubMed ID: 15345498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of rehabilitation in active ankylosing spondylitis assessed by the ASAS response criteria.
    Lubrano E; D'Angelo S; Parsons WJ; Corbi G; Ferrara N; Rengo F; Olivieri I
    Rheumatology (Oxford); 2007 Nov; 46(11):1672-5. PubMed ID: 17893100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of rehabilitation for patients with ankylosing spondylitis: comparison of a four-week rehabilitation programme in a Mediterranean and a Norwegian setting.
    Staalesen Strumse YA; Nordvåg BY; Stanghelle JK; Røisland M; Winther A; Pajunen PA; Garen T; Flatø B
    J Rehabil Med; 2011 May; 43(6):534-42. PubMed ID: 21491073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis.
    Brandt J; Listing J; Sieper J; Rudwaleit M; van der Heijde D; Braun J
    Ann Rheum Dis; 2004 Nov; 63(11):1438-44. PubMed ID: 15044211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists.
    Sidiropoulos PI; Hatemi G; Song IH; Avouac J; Collantes E; Hamuryudan V; Herold M; Kvien TK; Mielants H; Mendoza JM; Olivieri I; Østergaard M; Schachna L; Sieper J; Boumpas DT; Dougados M
    Rheumatology (Oxford); 2008 Mar; 47(3):355-61. PubMed ID: 18276738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonsteroidal antiinflammatory drug intake according to the Assessment of SpondyloArthritis International Society Score in clinical trials evaluating tumor necrosis factor blockers: example of etanercept in advanced ankylosing spondylitis.
    Dougados M; Braun J; Szanto S; Combe B; Geher P; Leblanc V; Logeart I
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):290-4. PubMed ID: 22006544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.
    Zochling J; van der Heijde D; Dougados M; Braun J
    Ann Rheum Dis; 2006 Apr; 65(4):423-32. PubMed ID: 16126792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT.
    van der Heijde D; Landewé R
    J Rheumatol; 2005 Oct; 32(10):2048-9. PubMed ID: 16206368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
    van der Heijde D; Da Silva JC; Dougados M; Geher P; van der Horst-Bruinsma I; Juanola X; Olivieri I; Raeman F; Settas L; Sieper J; Szechinski J; Walker D; Boussuge MP; Wajdula JS; Paolozzi L; Fatenejad S;
    Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment trials in ankylosing spondylitis: current and future considerations.
    van der Heijde D; Braun J; McGonagle D; Siegel J
    Ann Rheum Dis; 2002 Dec; 61 Suppl 3(Suppl 3):iii24-32. PubMed ID: 12381508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Patient evaluation of the German version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis].
    Kiltz U; Feldtkeller E; Braun J
    Z Rheumatol; 2008 Dec; 67(8):694-700, 702. PubMed ID: 19011877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Adjunctive treatment of axial undifferentiated spondyloarthritis by Qiangji Recipe: a clinical study].
    He MY; Fan FY
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jan; 35(1):37-40. PubMed ID: 25790672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews.
    Andreasen RA; Kristensen LE; Baraliakos X; Strand V; Mease PJ; de Wit M; Ellingsen T; Hansen IMJ; Kirkham J; Wells GA; Tugwell P; Maxwell L; Boers M; Egstrup K; Christensen R
    Arthritis Res Ther; 2020 Jul; 22(1):177. PubMed ID: 32711571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion.
    Lavie F; Pavy S; Dernis E; Goupille P; Cantagrel A; Tebib J; Claudepierre P; Flipo RM; Le Loët X; Maillefert JF; Mariette X; Saraux A; Schaeverbeke T; Wendling D; Combe B
    Joint Bone Spine; 2007 Jul; 74(4):346-52. PubMed ID: 17590370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
    Davis JC; Revicki D; van der Heijde DM; Rentz AM; Wong RL; Kupper H; Luo MP
    Arthritis Rheum; 2007 Aug; 57(6):1050-7. PubMed ID: 17665483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety and efficacy of Guluronic acid (G2013) in ankylosing spondylitis: A randomized controlled parallel clinical trial.
    Nazeri S; Jamshidi AR; Mahmoudi M; Vojdanian M; Khadem Azarian S; Afraei S; Mostafaei S; Hosseini M; Mirshafiey A
    Pharmacol Rep; 2019 Jun; 71(3):393-398. PubMed ID: 31003148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.